Analysis of Key Market Segments Driving the Oral Solid Dosage Contract Manufacturing Market

The oral solid dosage contract manufacturing sector is poised for significant expansion as demand for flexible and efficient pharmaceutical production rises. With innovations in manufacturing technologies and increasing outsourcing activities in emerging markets, this market is set to experience notable growth through 2030. Below, we explore the market size, key drivers, influential players, emerging trends, and segment-wise insights shaping this industry.

Projected Market Size and Growth Trajectory in the Oral Solid Dosage Contract Manufacturing Market
The oral solid dosage contract manufacturing market is forecasted to reach $59.05 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.7%. This upward trend is driven by the escalating need for scalable pharmaceutical manufacturing solutions, the growing pipeline of oral solid dosage drugs, and heightened investments in advanced manufacturing technologies. Additionally, expanding pharmaceutical outsourcing in emerging economies and the increasing demand for rapid, adaptable production capabilities are significant contributors to market growth. Key themes during this forecast period include the rising outsourcing of oral solid dosage manufacturing by pharmaceutical companies, higher demand for cost-effective, large-scale tablet and capsule production, and the growing use of modified and controlled release oral dosage forms. The industry also places a stronger emphasis on regulatory compliance and quality assurance, along with a preference for comprehensive end-to-end manufacturing and packaging services.

Download a free report of the oral solid dosage contract manufacturing market report:
https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-contract-manufacturing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Primary Drivers Fueling the Expansion of the Oral Solid Dosage Contract Manufacturing Market
A major factor propelling this market is the pharmaceutical industry's ongoing shift towards outsourcing manufacturing processes to third-party providers. This shift enables companies to focus on core competencies such as research and development, while benefiting from the specialized expertise and economies of scale that contract manufacturers offer.
Moreover, pharmaceutical companies are increasingly seeking scalable, flexible production options that can adapt quickly to changing market demands and regulatory requirements. This need drives investment in advanced manufacturing technologies and contract manufacturing organizations capable of delivering high-volume, cost-efficient oral solid dosage products.

Leading Companies Influencing the Oral Solid Dosage Contract Manufacturing Market
Key players dominating this market include Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operating as CordenPharma, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation, NextPharma AB, Delpharm, PCI Pharma Services, Adare Pharma, and Skyepharma.
In a strategic move to strengthen its pharmaceutical manufacturing capabilities, especially in oral solid dosage forms, US-based Jabil Inc. acquired Pharmaceutics International, Inc. (Pii) in February 2025 for $307 million. Pii is a CDMO providing early-stage, clinical, and commercial manufacturing services, including aseptic filling and lyophilization, which Jabil aims to integrate into its contract development and manufacturing offerings.

View the full oral solid dosage contract manufacturing market report:
https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-contract-manufacturing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Shaping the Oral Solid Dosage Contract Manufacturing Industry
Technological innovation is making a marked impact on the oral solid dosage contract manufacturing space. One important development is the growing use of personalized solutions and precision manufacturing to enhance product performance and patient outcomes.
In parallel, there is a rising focus on regulatory compliance and quality assurance, with manufacturers adopting stringent standards and advanced analytics to ensure product safety and efficacy. This is complemented by increasing demand for integrated end-to-end manufacturing and packaging services, which streamline supply chains and reduce time-to-market.

Market Segmentation and Forecast Insights in Oral Solid Dosage Contract Manufacturing
The oral solid dosage contract manufacturing market is broadly segmented by product type, service, therapeutic area, and end user.
By product type, the market includes tablets, capsules, powders, granules, and other oral dosage forms. Key tablet subcategories consist of compressed, effervescent, chewable, coated, and sustained or controlled release tablets. Capsule types include hard gelatin, soft gel, vegetarian, liquid-filled, and delayed release capsules. Powder forms cover powders for oral suspension, direct compression, mixing or blending, and instant dissolving powders. Granules are categorized into direct compression, tabletting, effervescent, and delayed or controlled release granules. Other product types encompass lozenges, oral strips, oral thin films, and effervescent tablets or granules.
Service-wise, the market covers drug product development, fill-finish product manufacturing, API manufacturing, packaging and labeling, and other applications. Therapeutic areas include oncology, cardiovascular diseases, metabolic disorders, neurological disorders, infectious diseases, gastrointestinal diseases, and other therapeutic segments. End users range from large pharmaceutical companies to medium and small-sized enterprises.

Regional Market Outlook and Growth Patterns
North America currently holds the largest share in the oral solid dosage contract manufacturing market, benefiting from advanced infrastructure and strong pharmaceutical activity. However, the Asia-Pacific region is expected to register the fastest growth rate in the coming years, driven by emerging markets, rising healthcare investments, and expanding pharmaceutical outsourcing.

In summary, the oral solid dosage contract manufacturing market is on a robust growth path supported by increased outsourcing, technological advancements, and evolving pharmaceutical pipelines. With key players strengthening capabilities and innovative trends shaping product development, this sector is positioned for sustained expansion through 2030 and beyond.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.